Klebsiella Infections Pipeline Insight 2025: Innovative Antibiotics and Novel Therapeutics Target the Growing AMR Threat | DelveInsight

DelveInsight's "Klebsiella Infections - Pipeline Insight, 2025" explores the evolving landscape of therapies aimed at tackling Klebsiella pneumoniae and related species, which are major culprits behind hospital-acquired infections, including pneumonia, bloodstream infections, and urinary tract infections. The rise of multidrug-resistant (MDR) and carbapenem-resistant strains has made Klebsiella a critical public health challenge with high morbidity and mortality.

The pipeline is advancing with novel β-lactam/β-lactamase inhibitor combinations, next-generation aminoglycosides, siderophore cephalosporins, and oxazolidinones designed to overcome resistant mechanisms. In parallel, non-traditional strategies such as bacteriophage therapy, antimicrobial peptides, immunotherapies, and microbiome-based approaches are being investigated to offer new avenues of treatment.

Clinical trials are evaluating endpoints such as microbiological clearance, clinical cure rates, and reduced mortality, with several late-stage candidates showing encouraging results. Regulatory agencies are backing these innovations with priority review, fast-track designations, and incentives for antimicrobial development.

With an urgent need for effective therapies against resistant Klebsiella infections, the pipeline is poised to deliver novel options that could reshape management and significantly improve patient outcomes.

Interested in learning more about the current treatment landscape and the key drivers shaping the Klebsiella Infections pipeline? Click here: https://www.delveinsight.com/report-store/klebsiella-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Klebsiella Infections Pipeline Report
• DelveInsight's Klebsiella Infections pipeline analysis depicts a strong space with 7+ active players working to develop 7+ pipeline drugs for Klebsiella Infections treatment.
• The leading Klebsiella Infections companies include Nosopharm, Debiopharm, Locus Biosciences, Inc., Inventprise, and others, who are evaluating their lead assets to improve the Klebsiella Infections treatment landscape.
• Key Klebsiella Infections pipeline therapies in various stages of development include NOSO-502, Debio 1454, LBP-KP01, IVT Klebsiella, and others.
• In March 2025, new research revealed a robust and multifaceted drug development pipeline targeting Klebsiella pneumoniae, including small-molecule antibiotics, antimicrobial peptides, antivirulence molecules, bacteriophage derivatives, and combination therapies.

Request a sample and discover the recent breakthroughs happening in the Klebsiella Infections pipeline landscape at https://www.delveinsight.com/report-store/klebsiella-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Klebsiella Infections Overview
Klebsiella species, particularly Klebsiella pneumoniae, are gram-negative bacteria commonly found in the human intestines but can cause serious infections when they spread to other parts of the body. These infections often occur in healthcare settings and include pneumonia, bloodstream infections, urinary tract infections, and surgical site infections. Klebsiella infections are especially concerning because many strains have developed resistance to multiple antibiotics, including carbapenems, making them difficult to treat.

Patients at higher risk for Klebsiella infections include those with weakened immune systems, prolonged hospital stays, invasive devices like ventilators or catheters, and prior antibiotic use. The rise of multidrug-resistant Klebsiella, particularly carbapenem-resistant K. pneumoniae (CRKP), poses significant challenges in clinical management, leading to increased morbidity, mortality, and healthcare costs. Prevention relies heavily on infection control measures such as hand hygiene, antimicrobial stewardship, and environmental cleaning in healthcare facilities.

Find out more about Klebsiella Infections medication at https://www.delveinsight.com/report-store/klebsiella-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Klebsiella Infections Treatment Analysis: Drug Profile
NOSO-502: Nosopharm
NOSO-502 is Nosopharm's first clinical candidate from a new class of antibiotics called odilorhabdins, which were discovered from Xenorhabdus bacteria. It is designed to treat major hospital-acquired infections caused by multidrug-resistant Enterobacteriaceae, including Escherichia coli, Klebsiella pneumoniae, and Enterobacter species. NOSO-502 works by inhibiting the bacterial ribosome through a novel mechanism of action. It shows activity against Carbapenem-Resistant Enterobacteriaceae (CRE), regardless of the type of carbapenemase enzyme they produce. These bacteria are responsible for severe, life-threatening infections in healthcare settings. Currently, NOSO-502 is in the preclinical stage of development for treating Klebsiella infections.

Debio 1454: Debiopharm
Debio 1454 is an antibiotic under development targeting multiple enteric bacterial species, including Acinetobacter baumannii, Enterobacter spp., Klebsiella pneumoniae, and E. coli. In 2019, Debiopharm received funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) in the U.S. to support the advancement of Debio 1454, particularly against multidrug-resistant A. baumannii, a major cause of highly resistant hospital-acquired pneumonia and classified by the WHO as a priority 1 critical pathogen. The drug is currently in the discovery stage of development for the treatment of Klebsiella infections.

Learn more about the novel and emerging Klebsiella Infections pipeline therapies at https://www.delveinsight.com/report-store/klebsiella-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Klebsiella Infections Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Klebsiella Infections Pipeline Report
• Coverage: Global
• Key Klebsiella Infections Companies: Nosopharm, Debiopharm, Locus Biosciences, Inc., Inventprise, and others.
• Key Klebsiella Infections Pipeline Therapies: NOSO-502, Debio 1454, LBP-KP01, IVT Klebsiella, and others.

To dive deep into rich insights for drugs used for Klebsiella Infections treatment, visit: https://www.delveinsight.com/report-store/klebsiella-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Klebsiella Infections Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Klebsiella Infections Pipeline Therapeutics
6. Klebsiella Infections Pipeline: Late-Stage Products (Phase III)
7. Klebsiella Infections Pipeline: Mid-Stage Products (Phase II)
8. Klebsiella Infections Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.